DAIDSDivision of Aids (National Institutes of Health)
DAIDSDivision of Acquired Immunodeficiency Syndrome (US NIH)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Fishbein, assuredly not much of a team player and oddly determined to take his oversight responsibilities seriously, filed a formal complaint against the deputy director of DAIDS, Dr.
Fishbein's firing discussed the NIH report and provided a very unflattering portrait of the DAIDS:
As the DAIDS scandal exploded in the press and as government investigations continued, finally, in 2006, the NIH hierarchy forced DAIDS to reinstate Dr.
This cataclysmic change, in terms of the DAIDS funding world, has come in the form of diminishing funding resources.
In theory, the recent reorganization of all of the DAIDS networks was necessary and a long time in coming.
There was a liver biopsy, however, which revealed, according to internal communiques of DAIDS staff, that Hafford had died of liver failure brought on by nevirapine toxicity.
On August 8, 2003, Jonathan Fishbein, who had recently taken a job as the director of the Office for Policy in Clinical Research Operations at DAIDS, wrote an email to his boss, DAIDS director Ed Tramont, alerting him that "there was a fulminant liver failure resulting in death" in a DAIDS trial and that it looked like "nevirapine was the likely culprit." He said that the FDA was being informed.
Fishbein alleged "widespread scientific and professional misconduct at the NIH Division of AIDS (DAIDS)" (quote from Honestdoctor.org).
Under "Definitions" it has a list of acronyms, a list of people with their titles, and even organizational diagrams of NIAID and DAIDS; it will also have a glossary.
For the unrestricted case, the partial-adjustment model shows extremely high correlations relations with the AIDS model and very high correlations with the DAIDS and TAIDS models.
We may draw two conclusions from these results: firstly, dynamic specification does matter and in one sense more so than deterministic specification, given that the DAIDS model shows higher correlations with the ROTT and CBS models than it does with the AIDS or TAIDS model (compare Tables 2 and 4).
However, according to Bridges, HAART offers a second chance for such vaccines to be studied, and this area of research is a high priority for the basic science program at DAIDS. The goal of this approach would not be to cure HIV, but to allow infected individuals to better control viremia, to build better immune responses, and to spend less time on HAART.